Dynamics of vessel wall changes following the implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months

• DOI: 10.4244/eijv9i11a217
• Publication Date: 2014-04-23T08:22:34Z
• Authors: Patrick W. Serruys; Yoshinobu Onuma; Hector M. Garcia-...; Takashi Muramatsu; Robert-Jan van Geuns; Bernard de Bruyne; Dariusz Dudek; Leif Thuesen; Pieter C. Smits; Bernard Chevalier; Dougal McClean; Jacques Koolen; Stephan Windecker; Robert Whitbourn; Ian Meredith; Cecile Dorange; Susan Veldhof; Karine Miquel Hebert; Richard Rapoza; John A. Ormiston
• Keywords: Intravascular Ultrasound; Lumen (anatomy); Bioresorbable scaffold; Everolimus

To assess observations with multimodality imaging of the Absorb bioresorbable everolimus-eluting vascular scaffold performed in two consecutive cohorts patients who were serially investigated either at 6 and 24 months or 12 36 months.In ABSORB multicentre single-arm trial, 45 (cohort B1) 56 B2) underwent serial invasive imaging, specifically quantitative coronary angiography (QCA), intravascular ultrasound (IVUS), radiofrequency backscattering (IVUS-VH) optical coherence tomography (OCT). Between one three years, late luminal loss remained unchanged (6 months: 0.19 mm, 1 year: 0.27 2 years: 3 0.29 mm) in-segment angiographic restenosis rate for entire cohort B (n=101) years was 6%. On IVUS, mean lumen, scaffold, plaque vessel area showed enlargement up to years. Mean lumen stable between whereas significant reduction behind struts occurred a trend toward adaptive restrictive remodelling EEM. Hyperechogenicity wall, surrogate bioresorption process, decreased from 23.1% 10.4% dense calcium necrotic core. At count strut cores detected on OCT increased significantly, probably reflecting dismantling scaffold; 98% covered. In (n=101), three-year major adverse cardiac event 10.0% without any thrombosis.The current investigation demonstrated dynamics wall changes after implantation resulting dimensions, low clinical events rate.http://www.clinicaltrials.gov/ct2/show/NCT00856856.